Clinical Trials
4 trialsNCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT02423603 2025-03-10
PAKT
Queen Mary University of London
Phase 2 Completed
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02077569 2017-05-04
STAKT
University of Nottingham
Phase 2 Completed